The medicine Enhertu has fam-trastuzumab deruxtecan-nxki as the active ingredient. The drug, Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate recommended for treating adult patients with breast cancer, non-small cell lung cancer and gastric or gastroesophageal junction adenocarcinoma. This drug comes in 100 mg lyophilized powder in a single-dose vial for intravenous infusion.
Indications
One can use the medicine Enhertu 100 mg for treating patients with:
HER2-positive breast cancer
Healthcare professionals recommend this medicine to adult patients who have unresectable/metastatic HER2-positive breast cancer who have received a prior anti-HER2-based routine either:
in the metastatic setting, or
in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of treatment completion.
HER2-low breast cancer
Healthcare providers indicate Enhertu in adult patients with unresectable/metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast carcinoma who have receive chemotherapy earlier in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Non-small cell lung cancer (NSCLC)
Adult patients are recommended to take Enhertu with unresectable/metastatic non-small cell lung cancer whose tumors have activating HER2 (ERBB2) mutations, detected by an FDA-approved test, and who have received systemic therapy earlier.
Gastric or gastroesophageal junction adenocarcinoma
Healthcare professionals recommend administering Enheru to adult patients who have locally advanced or metastatic HER2-positive gastric/gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen earlier.
Dosage
One should not substitute Enhertu for or with trastuzumab or ado-trastuzumab emtansine.
One can slow or interrupt the infusion rate if the patient develops infusion-related symptoms.
One should permanently discontinue Enhertu in case of severe infusion reactions.
Dosage for Metastatic Breast Cancer
Enhertu recommended dosage is 5.4 mg/kg administered intravenously once every 3 weeks (21-day) until disease progression or unacceptable toxicity.
Dosage for Unresectable or Metastatic HER2-Mutant (NSCLC)
Enhertu 100 mg injection recommended dosage is 5.4 mg/kg administered intravenously once every 3 weeks (21-day) until disease progression or unacceptable toxicity.
Locally Advanced or Metastatic Gastric Cancer Dosage
Enhertu recommended dosage is 6.4 mg/kg administered intravenously once every 3 weeks (21 days) until disease progression or unacceptable toxicity.
Price: Enhertu
If you want to buy enhertu online in India, contact us at +91 93100 90915 or at info@theindianpharma.com.